{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:46:59Z","timestamp":1785782819345,"version":"3.56.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,2,5]],"date-time":"2010-02-05T00:00:00Z","timestamp":1265328000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00417-010-1303-3","type":"journal-article","created":{"date-parts":[[2010,2,4]],"date-time":"2010-02-04T09:50:08Z","timestamp":1265277008000},"page":"785-791","source":"Crossref","is-referenced-by-count":84,"title":["Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy"],"prefix":"10.1007","volume":"248","author":[{"given":"Raffaello","family":"di Lauro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pio","family":"De Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"di Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"di Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Rosario","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,5]]},"reference":[{"key":"1303_CR1","first-page":"1929","volume":"37","author":"A Avanta","year":"1996","unstructured":"Avanta A, Algvere PV, Berglin L, Seregard S (1996) Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37:1929\u20131934","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1303_CR2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.81.2.154","volume":"81","author":"M Kliffen","year":"1997","unstructured":"Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT (1997) Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81:154\u2013162","journal-title":"Br J Ophthalmol"},{"key":"1303_CR3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/mvre.2002.2407","volume":"64","author":"A Otani","year":"2002","unstructured":"Otani A, Taxagi H, Oh H, Koyama S, Ogura Y, Matumura M, Honda Y (2002) Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 64:162\u2013169","journal-title":"Microvasc Res"},{"key":"1303_CR4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","volume":"118","author":"AP Adamis","year":"1994","unstructured":"Adamis AP, Miller JW, Bernal MT, D\u2019Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445\u2013450","journal-title":"Am J Ophthalmol"},{"key":"1303_CR5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487","journal-title":"N Engl J Med"},{"key":"1303_CR6","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","volume":"114","author":"MJ Tolentino","year":"1996","unstructured":"Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP (1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in non humane primate. Arch Ophthalmol 114:964\u2013970","journal-title":"Arch Ophthalmol"},{"key":"1303_CR7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0161-6420(98)92782-8","volume":"105","author":"RC Tripathi","year":"1998","unstructured":"Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP (1998) Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 105:232\u2013237","journal-title":"Ophthalmology"},{"key":"1303_CR8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0002-9440(10)65004-3","volume":"156","author":"K Lashkari","year":"2000","unstructured":"Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N (2000) Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 156:1337\u20131334","journal-title":"Am J Pathol"},{"key":"1303_CR9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","volume":"25","author":"AP Adamis","year":"2005","unstructured":"Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111\u2013118","journal-title":"Retina"},{"key":"1303_CR10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/sonc.2002.37264","volume":"29","author":"N Ferrara","year":"2002","unstructured":"Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29:10\u201314","journal-title":"Semin Oncol"},{"key":"1303_CR11","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","volume":"92","author":"LP Aiello","year":"1995","unstructured":"Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF- receptor chimeric proteins. Proc Natl Acad Sci USA 92:10457\u201310461","journal-title":"Proc Natl Acad Sci USA"},{"key":"1303_CR12","first-page":"979","volume":"110","author":"Eyetech Study Group","year":"2003","unstructured":"Eyetech Study Group (2003) Antivascular endothelial growth factor therapy for subfoveal choroideal neovascularization secondary to age-related macular degeneration. Phase II study results. Am J Ophthalmol 110:979\u2013986","journal-title":"Am J Ophthalmol"},{"key":"1303_CR13","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805\u20132816","journal-title":"N Engl J Med"},{"key":"1303_CR14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"EW Ng","year":"2006","unstructured":"Ng EW, Svima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-VEGF optamer for ocular vascular disease. Nat Rev Drug Discov 5:123\u2013132","journal-title":"Nat Rev Drug Discov"},{"key":"1303_CR15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.ophtha.2006.02.027","volume":"113","author":"VEGF inhibition study in ocular neovascularization (V.I.S.I.O.N.) clinical trial group","year":"2006","unstructured":"VEGF inhibition study in ocular neovascularization (V.I.S.I.O.N.) clinical trial group (2006) Pegaptanib sodium for neovascular age-related macular degeneration. two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophtalmology 113:992\u20131001","journal-title":"Ophtalmology"},{"key":"1303_CR16","first-page":"1508","volume":"113","author":"VEGF inhibition study in ocular neovascularization (V.I.S.I.O.N.) clinical trial group","year":"2006","unstructured":"VEGF inhibition study in ocular neovascularization (V.I.S.I.O.N.) clinical trial group (2006) Two-year efficacy results of the two randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113:1508\u20131525","journal-title":"Ophthalmology"},{"key":"1303_CR17","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ophtha.2005.01.043","volume":"112","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112:1048\u20131053","journal-title":"Ophthalmology"},{"key":"1303_CR18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ophtha.2006.01.027","volume":"113","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Hein JS, Hantsbarger G, Shams N (2006) Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 113:631\u2013632","journal-title":"Ophthalmology"},{"key":"1303_CR19","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","volume":"26","author":"N Ferrara","year":"2006","unstructured":"Ferrara N, D\u2019amico L, Shams N, Lowman M, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859\u2013870","journal-title":"Retina"},{"key":"1303_CR20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ophtha.2005.10.052","volume":"113","author":"JS Heier","year":"2006","unstructured":"Heier JS, Antoszyk AN, Pavak PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N (2006) Ranibizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 113:633\u2013642","journal-title":"Ophthalmology"},{"key":"1303_CR21","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"335","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 335:1419\u20131431","journal-title":"N Engl J Med"},{"key":"1303_CR22","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"335","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 335:1432\u20131444","journal-title":"N Engl J Med"},{"key":"1303_CR23","first-page":"391","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Millan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature 3:391\u2013400","journal-title":"Nature"},{"key":"1303_CR24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.seminoncol.2005.06.003","volume":"32","author":"J Marshall","year":"2005","unstructured":"Marshall J (2005) The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol 32:543\u2013547","journal-title":"Semin Oncol"},{"key":"1303_CR25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.iae.0000233327.68433.02","volume":"26","author":"PM Beer","year":"2006","unstructured":"Beer PM, Wong SJ, Hammad AM, Falk NS, O\u2019Malley MR, Khan S (2006) Vitreous level of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26:871\u2013876","journal-title":"Retina"},{"key":"1303_CR26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"JS Shahar","year":"2006","unstructured":"Shahar JS, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab. Retina 26:262\u2013269","journal-title":"Retina"},{"key":"1303_CR27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035\u20131047","journal-title":"Ophthalmology"},{"key":"1303_CR28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/01.iae.0000240121.28034.c3","volume":"26","author":"K Laud","year":"2006","unstructured":"Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960\u2013963","journal-title":"Retina"},{"key":"1303_CR29","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.iae.0000254896.78766.74","volume":"26","author":"A Tewari","year":"2006","unstructured":"Tewari A, Dhalla MS, Apte RS (2006) Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26:1093\u20131094","journal-title":"Retina"},{"key":"1303_CR30","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjo.2005.066431","volume":"89","author":"SD Nguyen","year":"2005","unstructured":"Nguyen SD, Sham S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA (2005) Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 89:1368\u20131370","journal-title":"Br J Ophthalmol"},{"key":"1303_CR31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative retinopathy complicated by vitreous hemorrhage. Retina 26:275\u2013278","journal-title":"Retina"},{"key":"1303_CR32","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/01.iae.0000246884.76018.63","volume":"26","author":"R Jorge","year":"2006","unstructured":"Jorge R, Costa RA, Calioli D, Cintra LP, Scott IU (2006) Intravitreal bevacizumab (avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26:1006\u20131013","journal-title":"Retina"},{"key":"1303_CR33","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","volume":"114","author":"JF Arevalo","year":"2007","unstructured":"Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME, Pan-American Collaborative Retina Study Group (2007) Primary intravitreal bevacizumab (avastin) for diabetic macular oedema. results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743\u2013750","journal-title":"Ophthalmology"},{"key":"1303_CR34","first-page":"39","volume":"38","author":"R Lauro di","year":"2007","unstructured":"di Lauro R, di Lauro R, de Ruggiero P, di Lauro MT, D\u2019Aloia A (2007) Bevacizumab (Avastin) preoperatorio nel trattamento chirurgico della retinopatia diabetica proliferante. Notiziario Soc Oftalmol It 38:39\u201345","journal-title":"Notiziario Soc Oftalmol It"},{"key":"1303_CR35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00006982-200603000-00005","volume":"26","author":"D Iturralde","year":"2006","unstructured":"Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279\u2013284","journal-title":"Retina"},{"key":"1303_CR36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ajo.2006.12.037","volume":"143","author":"SA Pai","year":"2007","unstructured":"Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601\u2013606","journal-title":"Am J Ophthalmol"},{"key":"1303_CR37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IAE.0b013e318030e77e","volume":"27","author":"MD Rabena","year":"2007","unstructured":"Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419\u2013425","journal-title":"Retina"},{"key":"1303_CR38","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00006982-200603000-00017","volume":"26","author":"FM Davidorf","year":"2006","unstructured":"Davidorf FM, Mouser JG, Derick RJ (2006) Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 26:354\u2013356","journal-title":"Retina"},{"key":"1303_CR39","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","volume":"142","author":"ME Iliev","year":"2006","unstructured":"Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf-Schnurrbursch U, Wolf S, Sarra GM (2006) Bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142:1054\u20131056","journal-title":"Am J Ophthalmol"},{"key":"1303_CR40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2125.2008.03278.x","volume":"66","author":"C Costagliola","year":"2008","unstructured":"Costagliola C, Cipollone U, Rinaldi M, della Corte M, Semeraro F, Romano MR (2008) Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol 66:667\u2013673","journal-title":"Br J Clin Pharmacol"},{"key":"1303_CR41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00006982-200603000-00018","volume":"26","author":"JO Mason","year":"2006","unstructured":"Mason JO, Albert MA Jr, Vail R (2006) Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 26:356\u2013360","journal-title":"Retina"},{"key":"1303_CR42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/08820530701420082","volume":"22","author":"H Quiroz-Mercado","year":"2007","unstructured":"Quiroz-Mercado H, Ustariz-Gonzales O, Martinez-Castellanos MA, Covarrubias P, Dominguez F, Sanchez-Huerta V (2007) Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Sem Ophthalmol 22:109\u2013125","journal-title":"Sem Ophthalmol"},{"key":"1303_CR43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","volume":"38","author":"A Travassos","year":"2007","unstructured":"Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, Prieto I, Pires G, van Velze R, Valido A, Machado Mdo C (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers 38:233\u2013237","journal-title":"Ophthalmic Surg Lasers"},{"key":"1303_CR44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1442-9071.2008.01805.x","volume":"36","author":"J Yeoh","year":"2008","unstructured":"Yeoh J, Williams C, Allen P, Buttery R, Chiu D, Clark B, Essex R, McCombe M, Qureshi S, Campbell WG (2008) Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol 36:449\u2013454","journal-title":"Clin Experiment Ophthalmol"},{"key":"1303_CR45","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/eye.2008.354","volume":"23","author":"MR Romano","year":"2008","unstructured":"Romano MR, Gibran SK, Marticorena J, Wong D, Heimann H (2008) Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? Eye 23:1698\u20131701","journal-title":"Eye"},{"key":"1303_CR46","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00417-008-0774-y","volume":"246","author":"S Rizzo","year":"2008","unstructured":"Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G (2008) Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 246:837\u2013842","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1303_CR47","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695","journal-title":"Ophthalmology"},{"key":"1303_CR48","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","volume":"146","author":"TU Krohne","year":"2008","unstructured":"Krohne TU, Eter N, Holz FG, Meyer CH (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146:508\u2013512","journal-title":"Am J Ophthalmol"},{"key":"1303_CR49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1440-1681.1999.03025.x","volume":"26","author":"T Warner","year":"1999","unstructured":"Warner T (1999) Relationships between the endothelin and nitric oxide pathways. Clin Exp Pharmacol Physiol 26:247\u2013252","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1303_CR50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331\u2013335","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"1303_CR51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363\u2013372","journal-title":"Ophthalmology"},{"key":"1303_CR52","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Laud K, Fine MF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383\u2013390","journal-title":"Retina"},{"key":"1303_CR53","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/01.iae.0000225351.87205.69","volume":"26","author":"E Chen","year":"2006","unstructured":"Chen E, Park CH (2006) Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26:699\u2013700","journal-title":"Retina"},{"key":"1303_CR54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","volume":"92","author":"JF Arevalo","year":"2008","unstructured":"Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213\u2013216","journal-title":"Br J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-010-1303-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-010-1303-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-010-1303-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T13:52:47Z","timestamp":1711201967000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-010-1303-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,5]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["1303"],"URL":"https:\/\/doi.org\/10.1007\/s00417-010-1303-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,5]]}}}